BiotechTube
Procos

Procos

Milan, Italy· Est.
procos.it
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Procos is a well-established, revenue-generating CDMO with over 40 years of operational history, providing end-to-end API services from R&D to commercial manufacturing. Its core strengths lie in a robust regulatory track record with approvals from the FDA, PMDA, and AIFA, and a significant investment in a 155,000 sq. meter facility. As part of the CBC Group, Procos leverages an international commercial network while maintaining deep roots in the Italian pharmaceutical manufacturing sector, positioning it as a strategic partner for pharmaceutical companies seeking reliable API production and development capabilities.

Medical Devices

Technology Platform

Integrated CDMO infrastructure for API development and manufacturing, including R&D, scale-up, multi-purpose cGMP production (including HPAPI capabilities), and a robust quality/compliance system with FDA, PMDA, and AIFA approvals.

Opportunities

Growth in the outsourced API manufacturing market, particularly in the high-potency (HPAPI) segment for complex therapies like oncology.
Leveraging its FDA/PMDA-approved European facility and CBC Group's international network to capture business from global pharmaceutical companies seeking reliable, quality-focused CDMO partners.

Risk Factors

Regulatory non-compliance at its main manufacturing site could severely damage its reputation and business.
The company faces intense competition in the CDMO space, including pressure on pricing, especially for generic APIs.
Revenue is project-based and subject to client concentration and pipeline volatility.

Competitive Landscape

Procos competes in the global pharmaceutical CDMO market against large players like Lonza, Catalent, and Siegfried, as well as numerous specialized and regional API manufacturers. Its differentiation is based on its large-scale, EU-based cGMP facility with a strong regulatory history, its HPAPI capabilities, and its integration within the CBC Group's network.

More companies in Small Molecule Drugs →More companies in Italy →